Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 109055
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109055
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109055
Quantitative immunohistochemistry analysis of pancreatic adenocarcinoma upregulated factor expression in pancreatic cancer and its prognostic significance
Jae Hyeong Kim, Kwangrok Jung, Dayeon Jang, Yuna Youn, Jin-Hyeok Hwang, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si 13620, Gyeonggi-do, South Korea
Hee Young Na, Department of Pathology, Seoul National University Bundang Hospital, Seongnam-si 13620, Gyeonggi-do, South Korea
Hee Young Na, Department of Pathology and Translational Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea
Dae Hwan Kim, Hee Dong Han, Prestige Biopharma Innovative Discovery Centre, Busan 46726, South Korea
Jin-Hyeok Hwang, Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea
Co-first authors: Jae Hyeong Kim and Hee Young Na.
Author contributions: Kim JH and Na HY contributed equally to this work and are considered co-first authors; Kim JH designed the study, acquired the data, performed statistical analysis, and drafted the manuscript; Na HY performed immunohistochemistry staining, interpreted pathological data, and contributed to data analysis; Jung K, Jang D, and Youn Y participated in sample collection, experimental procedures, and data curation; Kim DH and Han HD contributed to clinical data interpretation and critical review of the manuscript; Hwang JH conceptualized and supervised the study, secured funding, and revised and finalized the manuscript. All authors read and approved the final manuscript.
Supported by Seoul National University Bundang Hospital Research Fund, No. 06-2021-0140; and National Research Foundation of Korea, No. RS-2024-00335454.
Institutional review board statement: This study was approved by the Institutional Review Board of Seoul National University Bundang Hospital, No. B-2103-675-106.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The data that support the findings of this study are available on request from the corresponding author.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Hyeok Hwang, MD, PhD, Professor, Department of Internal Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173 Beon-gil, Seongnam-si 13620, Gyeonggi-do, South Korea. jhhwang@snubh.org
Received: May 9, 2025
Revised: July 4, 2025
Accepted: August 4, 2025
Published online: September 15, 2025
Processing time: 138 Days and 0.9 Hours
Revised: July 4, 2025
Accepted: August 4, 2025
Published online: September 15, 2025
Processing time: 138 Days and 0.9 Hours
Core Tip
Core Tip: This study reveals that pancreatic adenocarcinoma upregulated factor is overexpressed in pancreatic ductal adenocarcinoma and displays a significant relationship with metastasis to lymph nodes. High pancreatic adenocarcinoma upregulated factor expression correlates with shorter overall survival and independently predicts poor prognosis, supporting its role as a biomarker for patient stratification and targeted therapy development.